Glioma Biomarkers
Glioma Biomarkers - Related Videos
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
0 Views •
Cited by 10 •
2019
Neurospheres grown as 3D cultures constitute a powerful tool to study glioma biology. Here we present a protocol to perform immunohistochemistry while maintaining the 3D structure of glioma neurospheres through paraffin embedding. This method enables the characterization of glioma neurosphere properties such as stemness and neural differentiation.
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
0 Views •
2026
This protocol successfully prepared sufficient high-quality neovascular tissue from glioma samples using laser-capture microdissection for quantitative proteomics analysis of tumor angiogenesis, overcoming the limitations of studies that traditionally focus mainly on angiogenic factors and providing a large-scale proteomics profile of glioma angiogenesis.
02:41
Assessing Glutamatergic Neurons and Glioma Cells Interactions in a Co-Culture
0 Views •
2025
This video demonstrates the assessment of neuronal electrical activity in a co-culture of hiPSC-derived cortical glutamatergic neurons and glioma cells using a microfluidic device with multielectrode arrays.
04:27
Co-culturing Glutamatergic Neurons and Pediatric High-Grade Glioma Cells
0 Views •
2025
This video showcases a technique for co-culturing glutamatergic neurons and pediatric high-grade glioma (pHGG) cells within a microfluidic device. Human induced pluripotent stem cells are introduced into the microfluidic system and incubated to promote their differentiation into mature cortical glutamatergic neurons. Following this, the pHGG cells are introduced onto the mature neurons, establishing a co-culture and enabling interactions between neurons and pHGG cells.
03:55
Isolation of Nuclei from Fresh Frozen Glioma Tissues: A Method to Obtain Intact Nuclei from Glioma Tumor Samples
0 Views •
2023
This video describes the protocol to isolate single-nuclei from fresh frozen glioma tissue. The isolated single-nuclei can be used as specimens for sequencing techniques such as single-nuclei RNA (snRNA) sequencing and single-nuclei Assay for Transposase-Accessible Chromatin (snATAC) sequencing to obtain deeper insights into inter- and intra-tumor heterogeneity observed in glioma of the central nervous tissues.
FAQs
IDH mutation status and 1p/19q codeletion provide complementary classification signals. IDH status identifies a mutation-associated tumor feature, while codeletion records the loss of specific chromosome regions. Considering these findings together helps researchers and clinicians distinguish glioma subtypes more precisely than relying on a single characteristic, supporting diagnosis and downstream clinical decisions.
MGMT promoter methylation can indicate potential sensitivity to temozolomide, making it relevant to treatment selection. The marker reflects an epigenetic change in the tumor rather than a mutation or imaging feature. Its value is therefore predictive: it helps identify patients whose tumors may respond to this therapy and supports more informed treatment planning.
They can reflect tumor lineage, mutations, epigenetic changes, cellular behavior, and treatment response. This broader information connects a tumor’s molecular or cellular characteristics with clinically important questions, including prognosis, progression, and resistance. As a result, biomarkers can support both biological investigation and decisions that extend beyond naming a glioma subtype.
Each biomarker category captures a different aspect of the disease. Molecular and genetic features can characterize tumor identity, epigenetic markers can inform treatment sensitivity, cellular features can reflect behavior, and imaging features can help follow disease changes. Combining these perspectives may produce a more informative assessment than any single measurement, particularly when studying progression or resistance.
Researchers and clinicians first use relevant biomarker findings to characterize the tumor, including subtype-associated features such as IDH status and 1p/19q codeletion. They then consider markers linked to prognosis or treatment response, such as MGMT promoter methylation. The resulting profile can guide classification, therapy selection, progression monitoring, and investigation of resistance.
Biomarker assessment can help track disease progression and treatment response, rather than serving only as an initial classification tool. Patterns in relevant molecular, cellular, or imaging features may provide information about how the tumor behaves during management. This longitudinal perspective supports research into progression and resistance and may inform subsequent clinical decisions.
Biomarkers allow investigators to group patients according to tumor characteristics, expected prognosis, or potential treatment sensitivity. For example, IDH status, 1p/19q codeletion, and MGMT promoter methylation can separate biologically or clinically relevant groups. Such stratification makes research comparisons more precise and supports investigation of personalized treatment strategies.
Continued research aims to improve early detection, refine patient stratification, and develop more personalized treatment strategies. It also helps investigators examine why tumors progress or resist therapy by connecting measurable features with disease behavior and response. These goals are important because gliomas are complex brain tumors with multiple clinically relevant characteristics.